
Opinion|Videos|October 7, 2024
Navigating ICI Plus TKI Combinations for First-Line mRCC: Key Factors in Decision-Making
Author(s)Rana R. McKay, MD
Panelists discuss how they approach selecting among various immune checkpoint inhibitor (ICI) plus tyrosine kinase inhibitor (TKI) combinations for first-line treatment of metastatic renal cell carcinoma, considering key factors that influence their decision-making process and drawing insights from recent clinical trials such as CheckMate 9ER, KEYNOTE-426, and CLEAR.
Advertisement
Episodes in this series

- In your practice, how do you approach selection among the various immune checkpoint inhibitor plus tyrosine kinase inhibitor combinations for first-line treatment of metastatic renal cell carcinoma? What key factors influence your decision?
- CheckMate 9ER
- KEYNOTE-426
- CLEAR
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5




















